Literature DB >> 12165500

CD30 expression identifies the predominant proliferating T lymphocyte population in human alloimmune responses.

Keith W Chan1, Corwyn D Hopke, Sheri M Krams, Olivia M Martinez.   

Abstract

CD30 is an inducible member of the TNFR superfamily that is expressed on activated T and B cells and some lymphoid malignancies. We have previously shown that human CD30(+) T cells elicited with allogeneic APC are a major source of IFN-gamma and IL-5 production. In the present study we have used alloantigen, as well as anti-CD3 plus anti-CD28 mAb stimulation, to further characterize human CD30(+) T cells with respect to function and the expression of other activation-dependent cell surface molecules, including the related TNFR family members OX-40 and 4-1BB (CD137). Our results indicate that human CD30(+) T cells are a subset of activated T cells that also express CD25 and CD45RO. Moreover, we observed that allogeneic APC consistently induced a greater proportion of CD30(+) cells within the activated T cell population than did stimulation with plate-bound anti-CD3 plus anti-CD28 mAb or stimulation with soluble anti-CD3 plus anti-CD28 and autologous APC. The enhanced induction of CD30 expression by alloantigen was not common to other inducible TNFR family members because anti-CD3 plus anti-CD28 mAbs were far more effective in inducing expression of 4-1BB and OX-40. Furthermore, CD30 expression marked the predominant proliferating T cell population induced by alloantigen as determined by CFSE staining and flow cytometry. These results indicate that CD30, but not 4-1BB or OX-40, is preferentially induced by alloantigen, suggesting that CD30 may be important in human alloimmune responses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12165500     DOI: 10.4049/jimmunol.169.4.1784

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Expression of CD30 in patients with acute graft-versus-host disease.

Authors:  Yi-Bin Chen; Sean McDonough; Robert Hasserjian; Heidi Chen; Erin Coughlin; Christina Illiano; In Sun Park; Madan Jagasia; Thomas R Spitzer; Corey S Cutler; Robert J Soiffer; Jerome Ritz
Journal:  Blood       Date:  2012-06-01       Impact factor: 22.113

2.  CD30 Expression Is Rare in Myeloid Leukemia Cutis: A Study of 55 Cases and Implications for Routine Diagnostic Algorithms.

Authors:  Olakunle Ogunrinade; David Terrano; April Chiu; Melissa Pulitzer
Journal:  Am J Dermatopathol       Date:  2017-05       Impact factor: 1.533

Review 3.  Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD).

Authors:  Bruce R Blazar; William J Murphy
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-09-29       Impact factor: 6.237

4.  Activated T cell subsets in human type 1 diabetes: evidence for expansion of the DR+ CD30+ subpopulation in new-onset disease.

Authors:  C Baker; L Chang; K A Elsegood; A J Bishop; D H Gannon; P Narendran; N J Leech; C M Dayan
Journal:  Clin Exp Immunol       Date:  2007-03       Impact factor: 4.330

5.  Design and Assessment of Novel Anti-CD30 Chimeric Antigen Receptors with Human Antigen-Recognition Domains.

Authors:  Stephanie Choi; Melissa A Pegues; Norris Lam; Claudia Geldres; Danielle Vanasse; James N Kochenderfer
Journal:  Hum Gene Ther       Date:  2021-02-22       Impact factor: 4.793

6.  Increased bone marrow (BM) plasma level of soluble CD30 and correlations with BM plasma level of interferon (IFN)-γ, CD4/CD8 T-cell ratio and disease severity in aplastic anemia.

Authors:  Qingqing Wu; Jizhou Zhang; Jun Shi; Meili Ge; Xingxin Li; Yingqi Shao; Jianfeng Yao; Yizhou Zheng
Journal:  PLoS One       Date:  2014-11-10       Impact factor: 3.240

7.  Soluble CD30, the Immune Response, and Acute Rejection in Human Kidney Transplantation: A Systematic Review and Meta-Analysis.

Authors:  Mohammad Mirzakhani; Mehdi Shahbazi; Roghayeh Akbari; Ivana Dedinská; Eghlim Nemati; Mousa Mohammadnia-Afrouzi
Journal:  Front Immunol       Date:  2020-02-28       Impact factor: 7.561

8.  Extracellular Vesicles as Biomarkers of Acute Graft-vs.-Host Disease After Haploidentical Stem Cell Transplantation and Post-Transplant Cyclophosphamide.

Authors:  Giuseppe Lia; Clara Di Vito; Stefania Bruno; Marta Tapparo; Lucia Brunello; Armando Santoro; Jacopo Mariotti; Stefania Bramanti; Elisa Zaghi; Michela Calvi; Lorenzo Comba; Martina Fascì; Luisa Giaccone; Giovanni Camussi; Eileen M Boyle; Luca Castagna; Andrea Evangelista; Domenico Mavilio; Benedetto Bruno
Journal:  Front Immunol       Date:  2022-01-25       Impact factor: 7.561

9.  Donor-specific antibodies require preactivated immune system to harm renal transplant.

Authors:  Caner Süsal; Bernd Döhler; Andrea Ruhenstroth; Christian Morath; Antonij Slavcev; Thomas Fehr; Eric Wagner; Bernd Krüger; Margaret Rees; Sanja Balen; Stela Živčić-Ćosić; Douglas J Norman; Dirk Kuypers; Marie-Paule Emonds; Przemyslaw Pisarski; Claudia Bösmüller; Rolf Weimer; Joannis Mytilineos; Sabine Scherer; Thuong H Tran; Petra Gombos; Peter Schemmer; Martin Zeier; Gerhard Opelz
Journal:  EBioMedicine       Date:  2016-06-05       Impact factor: 8.143

10.  Increased HIV-1 transcriptional activity and infectious burden in peripheral blood and gut-associated CD4+ T cells expressing CD30.

Authors:  Louise E Hogan; Joshua Vasquez; Kristen S Hobbs; Emily Hanhauser; Brandon Aguilar-Rodriguez; Rajaa Hussien; Cassandra Thanh; Erica A Gibson; Alexander B Carvidi; Louis C B Smith; Shahzada Khan; Martin Trapecar; Shomyseh Sanjabi; Ma Somsouk; Cheryl A Stoddart; Daniel R Kuritzkes; Steven G Deeks; Timothy J Henrich
Journal:  PLoS Pathog       Date:  2018-02-22       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.